"Oct. 10, 2011 -- A combination of two drugs -- the chemotherapy drug Fludara and the biologic drug Campath -- may allow people with hard-to-treat chronic lymphocytic leukemia (CLL) to live longer.
One of the most common blood cancers "...
Mechanism of Action
Campath (alemtuzumab) binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34+ cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of Campath (alemtuzumab) to the leukemic cells.
Campath (alemtuzumab) pharmacokinetics were characterized in a study of 30 previously treated B-CLL patients in whom Campath (alemtuzumab) was administered at the recommended dose and schedule. Campath (alemtuzumab) pharmacokinetics displayed nonlinear elimination kinetics. After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg). Systemic clearance decreased with repeated administration due to decreased receptor-mediated clearance (i.e., loss of CD52 receptors in the periphery). After 12 weeks of dosing, patients exhibited a seven-fold increase in mean AUC. Mean half-life was 11 hours (range 2 to 32 hours) after the first 30 mg dose and was 6 days (range 1 to 14 days) after the last 30 mg dose.
Comparisons of AUC in patients ≥ 65 years (n=6) versus patients < 65 years (n=15) suggested that no dose adjustments are necessary for age. Comparisons of AUC in female patients (n=4) versus male patients (n=17) suggested that no dose adjustments are necessary for gender.
The pharmacokinetics of Campath (alemtuzumab) in pediatric patients have not been studied. The effects of renal or hepatic impairment on the pharmacokinetics of Campath (alemtuzumab) have not been studied.
Previously Untreated B-CLL Patients
Campath (alemtuzumab) was evaluated in an open-label, randomized (1:1) active-controlled study in previously untreated patients with B-CLL, Rai Stage I-IV, with evidence of progressive disease requiring therapy. Patients received either Campath (alemtuzumab) 30 mg IV 3 times/week for a maximum of 12 weeks or chlorambucil 40 mg/m2 PO once every 28 days, for a maximum of 12 cycles.
Of the 297 patients randomized, the median age was 60 years, 72% were male, 99% were Caucasian, 96% had a WHO performance status 0-1, 23 % had maximum lymph node diameter ≥ 5cm, 34% were Rai Stage III/IV, and 8% were treated in the U.S.
Patients randomized to receive Campath (alemtuzumab) experienced longer progression free survival (PFS) compared to those randomized to receive chlorambucil (median PFS 14.6 months vs. 11.7 months, respectively). The overall response rates were 83% and 55% (p < 0.0001) and the complete response rates were 24% and 2% (p < 0.0001) for Campath (alemtuzumab) and chlorambucil arms, respectively. The Kaplan-Meier curve for PFS is shown in Figure 1.
Figure 1 Progression Free Survival in Previously Untreated B-CLL Patients1
1 Log-rank test adjusted for Rai Stage (I-II YS. II-IV).
Previously Treated B-CLL Patients
Campath (alemtuzumab) was evaluated in three multicenter, open-label, single arm studies of 149 patients with B-CLL previously treated with alkylating agents, fludarabine, or other chemotherapies. Patients were treated with the recommended dose of Campath (alemtuzumab) , 30 mg intravenously, three times per week for up to 12 weeks. Partial response rates of 21 to 31 % and complete response rates of 0 to 2% were observed.
Last reviewed on RxList: 10/16/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Campath Information
Campath - User Reviews
Campath User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.